Bang !! One down and another partnership to follow me thinks
Mesoblast will receive up to US$150 million in upfront and milestone payments prior to product launch, as well as further commercialisation milestone payments. These payments include commitments up to US$45 million within the first year comprising US$15 million on signing, US$20 million on receiving regulatory approval to begin a confirmatory Phase III trial in Europe, and US$10 million on certain clinical and manufacturing outcomes. Cumulative milestone payments could exceed US$1 billion depending on the final outcome of Phase III studies and patient adoption. Mesoblast will also receive tiered double digit royalties on product sales
Ann: Grunenthal and MSB Enter Strategic Partnership for Back Pain, page-3
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
76.5¢ |
Change
-0.010(1.29%) |
Mkt cap ! $873.4M | |||
| Open | High | Low | Value | Volume |
| 76.5¢ | 80.3¢ | 76.0¢ | $5.022M | 6.472M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 424489 | 76.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 76.5¢ | 3903 | 1 |
View Market Depth
| Last trade - 16.10pm 19/04/2024 (20 minute delay) ? |
|
|||||
|
Last
76.5¢ |
Change
-0.010 ( 1.20 %) |
||||
| Open | High | Low | Volume | ||
| 78.0¢ | 80.0¢ | 76.0¢ | 2064486 | ||
| Last updated 15.59pm 19/04/2024 ? | |||||
| MSB (ASX) Chart |